Exploring a mucoacting spray-dried nanoparticle-in-microparticle inhalable formulation for targeted pulmonary delivery of sorafenib in lung cancer therapy

In this study, we developed an inhalable Nano-in-Micro (NiM) system for localized delivery of Sorafenib (Sor) in non-small cell lung cancer (NSCLC) therapy. Sor was encapsulated into mucus-penetrating and folate-targeted polymeric nanoparticles (FA-PPP-NPs@Sor), produced starting from the α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA), functionalised with poly(lactic-co-glycolic acid) (PLGA), and folate-conjugated polyethylene glycol (PEG-FA) FA (DD<sub>PLGA</sub> = 3.3 mol %, DD<sub>PEG-FA</sub> ≈ 8 chains/molecule). Nanoprecipitation produced 109 nm particles, easy to redisperse, with a DL of 10 wt%, which showed a controlled release of the drug, about 8.4 wt% (pH 7.4) vs. 21.7 wt% (pH 5.5) in 24 h. A selective cytotoxicity towards A549 lung cancer cells via folate receptor-mediated internalization was found, being IC<sub>50</sub> = 18 ± 3.2 µM, significantly lower than those found both in 16HBE cells (IC<sub>50</sub> = 69 ± 3.1 µM and free Sor (IC<sub>50</sub> = 17.7 ± 2.3 µM). The receptor involvement was confirmed by competitive folate blocking, which raised IC<sub>50</sub> >100 µM. Wound healing assay performed to evaluate the ability of Sor-loaded nanoparticles to inhibit or reduce cell migration showed 27 % vs. 40 % wound closure at 48 h (NiM vs Sor). The nanoparticles were further incorporated into inhalable microparticles via spray drying (SD), using mannitol, leucine, N-acetylcysteine, and ammonium bicarbonate as functional excipients (yield 63 wt%, EE = 100 wt%, DL = 0.35 wt%). The spray dried NiM<sub>Sor</sub> microparticles exhibited a MMAD and a FPF, respectively, of 2.2 µm and 76 %, suitable for deep lung delivery. Furthermore, their storage at r.t. and dissolution in water reconstitutes the nanoparticle dispersion. Rheology tests demonstrated time- and concentration-dependent mucus thinning. Overall, this study presents a promising inhalable platform for targeted lung cancer therapy, combining targeted cytotoxicity, mucus penetration, controlled release, and favourable aerosol properties.

Authors

Institutions

Publication Details

Journal
International Journal of Pharmaceutics
Published
2025-10-17
DOI
https://doi.org/10.1016/j.ijpharm.2025.126290
Citations
1
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring a mucoacting spray-dried nanoparticle-in-microparticle inhalable formulation for targeted pulmonary delivery of sorafenib in lung cancer therapy

Cinzia Scialabba, Emanuela Fabiola Craparo, Gennara Cavallaro, Salvatore Emanuele Drago et al.
1 citations
International Journal of Pharmaceutics
Inhalation and Respiratory Drug Delivery
1.52
article

Exploring a mucoacting spray-dried nanoparticle-in-microparticle inhalable formulation for targeted pulmonary delivery of sorafenib in lung cancer therapy

Cinzia Scialabba, Emanuela Fabiola Craparo, Gennara Cavallaro, Salvatore Emanuele Drago, Federico Corsaro
article en
1 citations

Abstract

In this study, we developed an inhalable Nano-in-Micro (NiM) system for localized delivery of Sorafenib (Sor) in non-small cell lung cancer (NSCLC) therapy. Sor was encapsulated into mucus-penetrating and folate-targeted polymeric nanoparticles (FA-PPP-NPs@Sor), produced starting from the α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA), functionalised with poly(lactic-co-glycolic acid) (PLGA), and folate-conjugated polyethylene glycol (PEG-FA) FA (DD<sub>PLGA</sub> = 3.3 mol %, DD<sub>PEG-FA</sub> ≈ 8 chains/molecule). Nanoprecipitation produced 109 nm particles, easy to redisperse, with a DL of 10 wt%, which showed a controlled release of the drug, about 8.4 wt% (pH 7.4) vs. 21.7 wt% (pH 5.5) in 24 h. A selective cytotoxicity towards A549 lung cancer cells via folate receptor-mediated internalization was found, being IC<sub>50</sub> = 18 ± 3.2 µM, significantly lower than those found both in 16HBE cells (IC<sub>50</sub> = 69 ± 3.1 µM and free Sor (IC<sub>50</sub> = 17.7 ± 2.3 µM). The receptor involvement was confirmed by competitive folate blocking, which raised IC<sub>50</sub> >100 µM. Wound healing assay performed to evaluate the ability of Sor-loaded nanoparticles to inhibit or reduce cell migration showed 27 % vs. 40 % wound closure at 48 h (NiM vs Sor). The nanoparticles were further incorporated into inhalable microparticles via spray drying (SD), using mannitol, leucine, N-acetylcysteine, and ammonium bicarbonate as functional excipients (yield 63 wt%, EE = 100 wt%, DL = 0.35 wt%). The spray dried NiM<sub>Sor</sub> microparticles exhibited a MMAD and a FPF, respectively, of 2.2 µm and 76 %, suitable for deep lung delivery. Furthermore, their storage at r.t. and dissolution in water reconstitutes the nanoparticle dispersion. Rheology tests demonstrated time- and concentration-dependent mucus thinning. Overall, this study presents a promising inhalable platform for targeted lung cancer therapy, combining targeted cytotoxicity, mucus penetration, controlled release, and favourable aerosol properties.

International Journal of PharmaceuticsVol. 685
University of Palermo (IT)
Università degli Studi di Palermo
Openalex Percentile: Top 13%
Inhalation and Respiratory Drug Delivery
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.